The Conversation (0)
PetLife Pharmaceuticals announced the company is proposing adding new products to their line based on their research into scorpion venoms, which may have antibacterial and anti-inflammatory properties.
PetLife Pharmaceuticals (OTCQB:PTLF) announced the company is proposing adding new products to their line based on their research into scorpion venoms, which may have antibacterial and anti-inflammatory properties.
As quoted in the press release:
The action of most venoms may be due to the primary toxin but, also is likely influenced by other components in the venom. These components, even in small quantities, may hold the key to the true action of scorpion venom. The advantages of using natural venom, as opposed to synthetic venom, is that all components of the venom are included in the therapeutic formulation. The effect of certain venoms as anti-tumor agents has been cited in the literature. Aside from the known anti-tumorigenic action of the primary toxin, other components of the venom may explain the venom’s action on other disease state cells. The PetLife research team is evaluating the potential for scorpion venom-based therapy for common companion pet diseases, such as Lyme disease and arthritis.
Dr. Ralph Salvagno, CEO of PetLife, stated, “Traditionally, research in scorpion venom therapy has centered around the treatment of ‘envenomation,’ which is the scientific name for scorpion stings. Our research team recognizes the potential benefit of scorpion venom for the treatment of significant medical conditions that affect our pets and will continue with their research in this field. We hope to be able to add non-toxic natural-based treatment for several diseases to our portfolio in the future.”
Click here to read the full press release.
Source: www.accesswire.com
